GSK plc
$163.76B- Market cap
- $107.65B
- Debt
- +$44.87B
- Cash
- −$3.40B
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $107.65B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: GSK stock price at discount vs GGG $49.89 current versus $96.55 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GGG's multiple
Implied fair value · at GSK's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · GGG FY 2025 (ended Dec 26, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
Capital structure 100% equity / 0% debt · EV / Revenue 5.36x · EV / EBITDA 16.07x
GSK carries the larger enterprise value at $163.76B against $11.99B; GSK trades on the lower EV / Revenue multiple (3.71x vs 5.36x); GGG on the lower EV / EBITDA (16.07x vs 19.25x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
GRACO INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
0.00x
Net debt / EBITDA
Leverage against operating earnings
6.59x
-0.83x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$624.08M
Total debt
Interest-bearing obligations outstanding
$44.87B
$1.62M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
SPX Technologies, Inc.
GSK vs SPXC
IDEX CORP /DE/
GSK vs IEX
Trane Technologies plc
GSK vs TT
Ingersoll Rand Inc.
GSK vs IR
Xylem Inc.
GSK vs XYL
DOVER Corp
GSK vs DOV
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.